# Clarivate Pricing The Worst

> Clarivate's share price hits fresh lows despite asset divestment.
- Title: Clarivate Pricing The Worst · Seekingalpha | Shortify
- Summary: Clarivate's share price hits fresh lows despite asset divestment. Clarivate's share price fell to $1 billion equity value after $600 million life sciences…
- Keywords: clarivate, clvt, life sciences, divestment, leverage, pro forma ebitda, share price, money, business, Pricing, Worst, Seekingalpha
- Source: Seekingalpha — https://seekingalpha.com/article/4951845-clarivate-pricing-the-worst-as-the-business-still-has-chances
- Author: The Value Investor
- Published: 2026-10-04T13:43:30+00:00
- Read time: 1 min
- Topics: clarivate, clvt, life sciences, divestment, leverage, pro forma ebitda, share price, money, business
## Clarivate's share price
Clarivate's share price has plunged to fresh lows with equity value now around $1 billion.
## Life sciences divestment
Clarivate announced a $600 million divestment of its life sciences & healthcare segment.
## Leverage overhang
Clarivate continues to face a significant leverage overhang despite the divestment.
## Valuation metrics
Valuation is compelling at just over 2x sales and ~5x pro forma EBITDA.
## Key risks
High leverage and a $240 million annual interest bill remain key risks.
## Risk-reward outlook
I see the risk-reward as reasonable for a small, highly speculative position.
## Key takeaway

Clarivate's share price fell to $1 billion equity value after $600 million life sciences divestment, with valuation at 2x sales and 5x pro forma EBITDA.